Post by Silence Therapeutics plc

Why our approach in polycythemia vera (PV)? Our investigational siRNA therapy is designed to target TMPRSS6 with the goal of increasing hepcidin and reducing iron availability for red blood cell production. By targeting iron regulation, we are investigating a potential new approach for people living with PV. Learn more about our investigational siRNA approach in PV: https://bit.ly/4u67NgK